Core Viewpoint - Zhongyuan Qihua (600645) is advancing its clinical research in innovative therapies, focusing on treatments for idiopathic pulmonary fibrosis and chronic periodontitis [1] Group 1: Clinical Trials - The company's wholly-owned subsidiary, Wuhan Guanggu Pharmaceutical, is conducting a Phase I clinical trial for VUM02 injection aimed at treating idiopathic pulmonary fibrosis (IPF) [1] - The company holds a stake in Beijing Sanyouli, which is collaborating with Capital Medical University on a Phase II clinical trial for "human dental pulp mesenchymal stem cell injection" to treat chronic periodontitis [1] Group 2: Regulatory Compliance - The company's stem cell clinical research projects have been registered with the National Health Commission/NMPA and the Logistics Support Department of the Central Military Commission [1]

Core Viewpoint - Zhongyuan Xiehe announced that its affiliated company, Beijing Sanyouli, in collaboration with Capital Medical University, is progressing with the clinical trials of "human dental pulp mesenchymal stem cell injection" for the treatment of chronic periodontitis, with all participants for Phase II expected to be enrolled by 2024 [1] Group 1 - The company is conducting regular follow-up work for the chronic periodontitis treatment trial [1] - The treatment for idiopathic pulmonary fibrosis has completed all participant dosing in Phase I, and the company is currently organizing clinical safety and efficacy data [1]